NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Alight, Inc. ("Alight, Inc." or the "Company") (NYSE: ALIT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Alight, Inc. investors who were adversely affected by alleged securities fraud between November 12, 2024 and February 18, 2026. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/alight-inc-lawsuit ...

Core Viewpoint - A class action securities lawsuit has been filed against Picard Medical, Inc. for alleged securities fraud affecting investors between September 2, 2025, and October 31, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Picard Medical was involved in a fraudulent stock promotion scheme that utilized social media misinformation and impersonation of financial professionals [2]. - It is alleged that insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [2]. - The complaint states that Picard's public statements and risk disclosures failed to mention the false rumors and artificial trading activity that influenced the stock price [2]. - As a result of these actions, the defendants' positive statements regarding the Company's business and prospects were misleading and lacked a reasonable basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses in Picard Medical during the specified timeframe have until April 3, 2026, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Kyndryl Holdings, Inc. ("Kyndryl" or the "Company") (NYSE: KD) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Kyndryl investors who were adversely affected by alleged securities fraud between August 1, 2024 and February 9, 2026. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/kyndryl-holdings-lawsuit ...

NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Gartner, Inc. ("Gartner, Inc." or the "Company") (NYSE: IT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Gartner, Inc. investors who were adversely affected by alleged securities fraud between February 4, 2025 and February 2, 2026. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/gartner-inc-lawsuit ...

Core Viewpoint - A class action securities lawsuit has been filed against Corcept Therapeutics Incorporated, alleging securities fraud that affected investors between October 31, 2024, and December 30, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who were adversely affected by alleged securities fraud during the specified period [2]. - The complaint states that the defendants made false statements regarding their interactions with the FDA and the approval prospects of relacorilant, which were misleading given the FDA's concerns about the drug's effectiveness and the design of the GRACE study [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until April 21, 2026, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Law Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Soleno Therapeutics, Inc. for allegedly making false statements and failing to disclose material facts regarding its Phase 3 clinical trial for its product DCCR, which has led to significant financial losses for investors [2][5][6]. Company Overview - Soleno Therapeutics, Inc. is a pharmaceutical company based in Redwood City, California, focused on developing therapies for rare diseases. Its primary product is diazoxide choline extended-release tablets (DCCR), aimed at treating hyperphagia in individuals with Prader-Willi syndrome (PWS) [4]. Lawsuit Details - The lawsuit was filed on behalf of investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025. The case is registered in the United States District Court for the Northern District of California [2][6]. - Investors have until May 5, 2026, to file for lead plaintiff status in the class action [2][8]. Allegations - The complaint alleges that Soleno's executives made materially false and misleading statements regarding the safety and commercial viability of DCCR, including: 1. Downplaying safety concerns related to excess fluid retention in clinical trial participants [5]. 2. Misrepresenting the risks associated with DCCR, which could lead to adverse events post-commercial launch [5]. 3. Resulting in a decline in stock price by over 26% following the release of a critical report by Scorpion Capital [6][7]. Investor Actions - Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for recovery options at no cost. They can either seek to be appointed as lead plaintiffs or remain as absent class members [3][8].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Driven Brands Holdings Inc. for allegedly making materially false and misleading statements regarding its financial reporting and internal controls [2][4]. Group 1: Lawsuit Details - The lawsuit is filed on behalf of investors who purchased Driven Brands common stock between May 9, 2023, and February 24, 2026 [2][7]. - Investors have until May 8, 2026, to file for lead plaintiff status [2][8]. - The case is titled Clark v. Driven Brands Holdings Inc., et al, and is being heard in the United States District Court for the Southern District of New York [2]. Group 2: Allegations - The complaint alleges that Driven Brands misrepresented and failed to disclose significant errors in its financial statements, including issues with lease recording and cash flow reporting [4]. - Specific allegations include overstatements of cash and revenue, and misclassification of expenses in fiscal years 2023 and 2024 [4]. - The company also identified errors related to income tax provisions and revenue recognition, particularly in its ATI business for fiscal year 2025 [4]. Group 3: Stock Impact - Following the disclosure of the need to restate financial statements due to accounting errors, Driven Brands' stock price dropped by $5.01, nearly 40%, from $16.61 to $11.60 per share on February 25, 2026 [5].

Deadline Approaching: Gartner, Inc. (IT) Shareholders Who Lost Money Urged to Contact Law Offices of Howard G. Smith Mar 23, 2026 2:17 PM Eastern Daylight Time Deadline Approaching: Gartner, Inc. (IT) Shareholders Who Lost Money Urged to Contact Law Offices of Howard G. Smith Share BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming May 18, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Gartner, Inc. ("Gartner ...

Deadline Alert: ChowChow Cloud International Holdings Limited (CHOW) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit Mar 23, 2026 1:48 PM Eastern Daylight Time Deadline Alert: ChowChow Cloud International Holdings Limited (CHOW) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit IF YOU SUFFERED A LOSS ON YOUR CHOW INVESTMENTS, CLICK HERETO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECO ...

Core Viewpoint - Hercules Capital, Inc. is facing a securities fraud lawsuit due to allegations of misleading statements and inadequate due diligence in its deal sourcing and portfolio valuation processes, leading to significant financial losses for shareholders [2][4][5]. Group 1: Allegations and Findings - A report by Hunterbrook Media claims that Hercules Capital's deal sourcing process is inadequate, relying on external sources like Google Ventures instead of conducting its own due diligence [2]. - The report also highlights concerns regarding the company's valuation process, indicating a small team with insufficient checks, which may lead to inaccurate portfolio valuations [3]. - Allegations include misclassification of portfolio investments and overstating the company's financial health, particularly regarding software debt, which is marked at full value despite industry-wide distress [3][5]. Group 2: Stock Market Reaction - Following the release of the report on February 27, 2026, Hercules Capital's stock price dropped by $1.22, or 7.9%, closing at $14.21 per share, with unusually high trading volume [3]. Group 3: Legal Proceedings - Shareholders who suffered losses during the class period from May 1, 2025, to February 27, 2026, are encouraged to file a lead plaintiff motion by the deadline of May 19, 2026 [1][6].